How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

) has been revised to $6.12 / share. This is a decrease of 10.64% from the prior estimate of $6.85 dated April 25, 2026. The price target is an average of many targets provided by analysts. The latest ...

Move over karyotypes—genetic disorder detection has vastly improved. Researchers are now using array CGH (aCGH), to quickly scan through an entire genome for imbalances. Because aCGH facilitates ...

Try to find the Notes app on your phone — without using Spotlight search. If you've spent more than a minute hunting for this across your home screens, you may want to consider organizing your iPhone ...

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.